Study examined the use of circulating tumor DNA as a prognostic tool before and after treatment with CAR T therapy axicabtagene ciloleucel.
Home / Resource Library / Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial